Florian Gaertner/Photothek via Getty Images
- The quick rise of GLP-1 weight-loss drugs is set to drive a big shake-up in the stock market.
- The long-term ripple effects of these drugs will impact sectors across equities and economy.
- These are the areas to watch as drugs like Ozempic, Wegovy, and Mounjaro rise in popularity.
With the surging popularity of GLP-1 weight-loss drugs, millions of Americans are poised to collectively shed hundreds of millions of pounds over the next decade — and reshuffle trillions of dollars in the process.
In other words, the stock market is getting Ozempic'ed.